Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors

  title={Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors},
  author={Marja D. Van Sickle and Marnie Duncan and Philip J. Kingsley and Abdeslam Mouihate and Paolo Urbani and Ken Mackie and Nephi Stella and Alexandros Makriyannis and Daniele Piomelli and Joseph Davison and Lawrence J. Marnett and Vincenzo Di Marzo and Quentin J. Pittman and Kamala D Patel and Keith A. Sharkey},
  pages={329 - 332}
The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial. We report the expression of CB2 receptor messenger RNA and protein localization on brainstem neurons. These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors. CB2 receptors represent an alternative site of action of endocannabinoids that opens the… 

The therapeutic potential of novel cannabinoid receptors.

The central cannabinoid receptor type-2 (CB2) and chronic pain

Cannabinoid receptor type-2 (CB2, CB2 receptor or CB2-R) mediates analgesia via two mechanisms, and has been proposed as a potential target in treating chronic pain of several etiologies.

Molecular Biology of Cannabinoid Receptors: Mutational Analyses of the CB Receptors

The identification of GPR55 as another GPCR that responds to a diverse set of cannabinoids may herald a new era of molecular biology of cannabinoid receptors.

The cannabinoid CB2 receptor: a good friend in the gut

  • A. Izzo
  • Biology, Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2007
Evidence that CB2 receptor activation inhibits visceral afferent nerve activity in rodents is provided and highlighted in the context of recent data highlighting the emerging role of CB2 receptors as a critical target able to counteract hypermotility in pathophysiological states, gut inflammation and possibly colon cancer.

Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors

The aim of this study was to compare the pharmacology of CB2 receptor ligands in tissue natively expressing CB2 receptors (human, rat and mouse spleen) and hCB2‐transfected CHO cells.

Cannabinoid CB2 receptors in human brain inflammation

In this review some recent findings on the antiinflammatory properties of CB2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples.

Neuropsychobiological Evidence for the Functional Presence and Expression of Cannabinoid CB2 Receptors in the Brain

It is demonstrated that CB2 cannabinoid receptors and their gene transcripts are widely distributed in the brain and may therefore be exploited as new targets in the treatment of depression and substance abuse.

Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry

This review gathers the most relevant literature regarding new advances about the role of CB2R in a variety of neuropsychiatric conditions, with special emphasis on its potential as a new therapeutic target for the treatment of different psychiatric disorders.



Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study

This work has performed immunohistochemical analysis of tissue sections of white matter areas of the human cerebellum and detected the presence of CB2 receptors in perivascular microglial cells, which match with the well‐known immunomodulatory role ofCB2 receptors and open new perspectives on the possible role that these receptors may play in pathophysiological events.

Role of endogenous cannabinoids in synaptic signaling.

The synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation, and the fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 is described in most brain areas, emphasizing its general presynaptic localization and role in controlling neurotransmitter release.

International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking.

Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.

Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.

CB1r mediates the anti-emetic action of cannabinoids in the dorsal vagal complex and is found in the myenteric plexus of the stomach and duodenum and a novel neuroregulatory system involved in the control of emesis.

Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.

The data in this study suggest that the discrepancies in affinities between rat and human may represent species differences, and the rat CB( 2) receptor genomic clone will be a useful tool for studying the function and regulation of CB(2) in rats.

CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

The endogenous cannabinoid system provides on-demand protection against acute excitotoxicity in central nervous system neurons and could not be triggered in mutant mice.

The cannabinoid system and immune modulation

It appears the immunocannabinoid system is involved in regulating the brain‐immune axis and might be exploited in future therapies for chronic diseases and immune deficiency.

Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

Results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia, respectively, whereas the expression of CB1 receptors remains unchanged.